… (buparlisib/cetuximab), buparlisib monotherapy and cetuximab monotherapy is necessary. …
cetuximab monotherapy in head and neck cancer patients. In general, the RR of cetuximab …

… The primary aim of this study was to assess the relative dose intensity of cetuximab in
patients with R/M SCCHN treated with first-line cetuximab according to the EXTREME regimen. …

… This study aimed to analyze the clinical outcomes associated with patients with recurrent/metastatic
head and neck squamous cell carcinoma (RM HNSCC) who received cetuximab-…

… Background: Cetuximab, an epidermal growth factor receptor (EGFR)-targeting … for squamous
cell carcinoma (SCC) of head and neck/esophagus. However, in clinical trials, cetuximab …

… of cetuximab (C), 5-flourouracil, and cisplatin with the same regimen adding docetaxel (D) in
recurrent/metastatic head and neck cancer… squamous cell carcinoma of the head and neck (…

… and neck cancers, with 64,690 new cases and … head and neck cancers are squamous cell
carcinomas that arise in the squamous cells lining the mucosal surfaces inside the head and …

… of immune effector NK and CD8 T cells but not regulatory T cells. This phase I study evaluated
… cetuximab (CET) by SIM in patients (pts) with head and neck squamous cell carcinoma (…

… in cetuximab-resistant human papillomavirus (HPV)-unrelated head and neck squamous-cell
carcinoma (… In this study, we aimed to determine the proportion of patients with cetuximab-…

… to cetuximab therapy for head and neck cancer and … events from cetuximab therapy in head
and neck cancer treatment, of … The strongest risk factor for a serious outcome was cetuximab …

… Median OS was reported to be 9.7 months in palbociclib plus cetuximab group and 7.8
months in cetuximab group, showing a prolongation of median OS in combination group …